Microdosing GLP-1 (glucagon-like peptide-1) agonist weight loss drugs involves taking smaller doses of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or orforglipron (Foundayo) than recommended by the U.S
President Donald Trump told reporters he is considering AI "controls" in response, while adding he did not want to "restrict" developers from building new products, according to Reuters
This matters for interpretation: an intervention whose insulin-sensitizing effect is largely weight-mediated will help women whose insulin resistance is weight-driven more than it helps the intrinsic, lean-PCOS component that persists independent of body mass
In clinical trials, it has been tested at doses ranging from 1mg to 12mg, with a gradual titration schedule designed to reduce gastrointestinal side effects
Telehealth services like the Ro Body program are rushing to fill the gap